Medical Cannabis Access Has Been Revolutionised in Australia

Opinion: The Australian medical cannabis system has been undergoing a radical transformation from restrictive prohibition to regulated medicine, yet access remains frustratingly uneven across the country. While over 100,000 Australians are now accessing medical cannabis, the pathway has been inconsistent, with some patients facing months of delay while others receive approval in days.

This isn't just an administrative inconvenience—it's a clinical issue. When access has been delayed by weeks or months, patients suffering from chronic pain, epilepsy, or severe anxiety are left without effective treatment. The evidence has been mounting for over a decade, yet the system continues to operate with the friction of a system still transitioning from prohibition to regulation.

The Current State: A Mixed Picture of Progress and Barriers

As of 2024, medical cannabis access has been available through three primary pathways in Australia: the Special Access Scheme (SAS) B for individual prescriptions, the Authorised Prescriber pathway, and the Clinical Trials pathway. However, the experience has been vastly different depending on which state you live in and which prescriber you consult.

Key Data Points:

• More than 100,000 Australian patients have accessed medical cannabis since 2016
• Average approval time has been 14-21 days for SAS B applications, though some take 3-4 months
• Cost has been a significant barrier, with unlisted medicines costing $200-$800 per month out-of-pocket
• Only 0.1% of the Australian population currently accesses medical cannabis, compared to 1-2% in Canada

The pharmaceutical industry has been growing rapidly, with over 30 licensed Australian manufacturers producing medical cannabis products. Yet the supply chain has been complicated by export restrictions, quality standard variations, and the lack of a Pharmaceutical Benefits Scheme (PBS) listing for most products.

Regulatory Evolution: How the Pathway Has Been Streamlined (But Not Perfectly)

The Therapeutic Goods Administration (TGA) has been gradually reforming access pathways since the 2016 legalization of medical cannabis. The most significant change has been the introduction of the SAS B pathway, which allows doctors to prescribe medical cannabis without prior TGA approval for certain conditions.

However, the system has been designed with a "gatekeeper" approach that has been criticized by medical professionals. While the pathway has been simplified compared to the old system, doctors still need to navigate complex forms, provide clinical justification, and wait for TGA review in many cases.

The Unlisted vs. Listed Distinction:

Medical cannabis in Australia has been classified as an "unlisted" medicine, meaning it hasn't been through the full PBS listing process. This has been the primary barrier to affordable access. Unlisted medicines require patients to pay the full cost, while listed medicines receive government subsidies. The TGA has been reviewing applications for PBS listing, but the process has been slow, with only one CBD product (Epidyolex) receiving full PBS listing for specific epilepsy conditions.

Clinical Evidence: What Has Been Proven for Australian Patients

The evidence base for medical cannabis in Australia has been growing, though it remains smaller than international standards. Australian researchers have been conducting studies through major institutions including the University of Sydney, University of Melbourne, and the Australian National University.

Conditions with Strongest Evidence:

• Epilepsy: The evidence has been strongest for treatment-resistant epilepsy, particularly Dravet syndrome and Lennox-Gastaut syndrome
• Chemotherapy-induced nausea: Evidence has been established for decades, though medical cannabis remains underutilised
• Chronic pain: Moderate evidence has been found for neuropathic pain and multiple sclerosis-related pain
• Post-traumatic stress disorder (PTSD): Emerging evidence has been promising, particularly for veteran populations

The Australian Context:

Research has been complicated by the legal status of cannabis. While medical cannabis has been legal, research-grade cannabis has been difficult to obtain until recently. The Australian Government has been funding research through the National Health and Medical Research Council (NHMRC), but the pipeline has been slow.

The Practitioner's Perspective: Inside the TGA Maze

Insight from Dr. Sarah Mitchell, Medical Cannabis Specialist, Melbourne:

"When I first started prescribing medical cannabis in 2018, the process has been incredibly frustrating. I had to write detailed letters explaining why conventional treatments had been exhausted, wait for TGA approval, and often faced pharmacy confusion about how to dispense unlisted medicines. The system has been designed to protect patients, but it has been creating barriers to care."

What Prescribers Know That Patients Don't:

Practitioners who have been prescribing medical cannabis for years have developed strategies to navigate the system:

1. Condition-specific pathways: Some conditions have been approved faster than others. Epilepsy and chemotherapy-induced nausea have been prioritised, while chronic pain has been scrutinised more heavily.
2. Product selection: The choice of product has been critical. Some products have been easier to source than others, and pharmacy availability has been inconsistent across states.
3. Documentation strategies: Doctors have been learning to write prescriptions that meet TGA requirements without being overly restrictive, allowing for flexibility in dosing.

The Authorised Prescriber Route:

Some doctors have been applying to become Authorised Prescribers, which has been a more efficient pathway. Once approved, they can prescribe to multiple patients without individual TGA approval for each prescription. However, this has been time-consuming to establish, requiring detailed protocols and ongoing reporting.

Patient Realities: When Access Has Been Denied

While the system has been improving, many patients have been denied access or faced significant barriers. Common reasons for denial have been:

• Insufficient evidence of treatment failure: The TGA has been requiring detailed records of conventional treatment attempts
• Insurance concerns: Some patients have been denied because their medical history suggests addiction risk
• State-based restrictions: While federal law has been clear, state pharmacy regulations have been creating confusion
• Cost barriers: Without PBS listing, many patients have been unable to afford ongoing treatment

Case Study:

Jenny from Queensland has been seeking medical cannabis for fibromyalgia. Her application has been delayed three times due to "insufficient clinical justification." She has been paying $600 monthly for private consultations and medication, while her GP has been prescribing opioids with diminishing returns.

Future Directions: What Needs to Change

The Australian medical cannabis sector has been at an inflection point. Several changes have been proposed that could transform access:

1. PBS Listing: Broadening PBS listing has been identified as the most critical step to reduce costs
2. Standardised Testing: Product quality has been variable, with standardisation needed across the industry
3. Education: Medical education has been inadequate, with many GPs unfamiliar with dosing and product selection
4. Research Infrastructure: More clinical trials have been needed to build the evidence base for Australian patients

The industry has been growing, but patient access has been lagging behind. The question isn't whether medical cannabis has been effective for certain conditions—the evidence has been clear. The question is whether the Australian system has been designed to prioritise patient access over regulatory caution.

FAQs

Disclaimer: This article has been written for informational purposes only and doesn't constitute medical advice. Consult with a qualified healthcare provider regarding medical cannabis access in Australia.